Table 4.
Study | Agents | Population | PFS | OS |
---|---|---|---|---|
Bolis et al28 | Paclitaxel | No benefit | No benefit | |
Paclitaxel + epirubicin | ||||
Torri et al29 | Paclitaxel | 50% had resistant disease | No benefit | No benefit |
Paclitaxel + doxorubicin | ||||
Buda et al30 | Paclitaxel | 75% had resistant disease | No benefit | No benefit |
Paclitaxel + epirubicin | ||||
Sehouli et al31 | Topotecan | No benefit | No benefit | |
Topotecan + etoposide or gemcitabine | ||||
Monk et al18 | PLD | No benefit | No benefit | |
PLD + trabectedin | ||||
ET43-OVA-301 | weekly paclitaxel | No benefit | No benefit | |
Lortholary et al32 | weekly paclitaxel + carboplatin or weekly topotecan |
Abbreviations: OS, overall survival; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin.